DK3285772T3 - En specifik trifluorethylquinolinanalog til anvendelse ved behandlingen af sjögrens syndrom - Google Patents

En specifik trifluorethylquinolinanalog til anvendelse ved behandlingen af sjögrens syndrom Download PDF

Info

Publication number
DK3285772T3
DK3285772T3 DK16719356.4T DK16719356T DK3285772T3 DK 3285772 T3 DK3285772 T3 DK 3285772T3 DK 16719356 T DK16719356 T DK 16719356T DK 3285772 T3 DK3285772 T3 DK 3285772T3
Authority
DK
Denmark
Prior art keywords
trifluorethylquinoline
sjögren
analogue
syndrome
treatment
Prior art date
Application number
DK16719356.4T
Other languages
Danish (da)
English (en)
Inventor
Rodger Anthony Allen
Francesca Barone
William Anthony Fahy
Saba Nayar
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Application granted granted Critical
Publication of DK3285772T3 publication Critical patent/DK3285772T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK16719356.4T 2015-04-21 2016-04-20 En specifik trifluorethylquinolinanalog til anvendelse ved behandlingen af sjögrens syndrom DK3285772T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use
PCT/EP2016/058810 WO2016170014A1 (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome

Publications (1)

Publication Number Publication Date
DK3285772T3 true DK3285772T3 (da) 2020-01-13

Family

ID=53298950

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16719356.4T DK3285772T3 (da) 2015-04-21 2016-04-20 En specifik trifluorethylquinolinanalog til anvendelse ved behandlingen af sjögrens syndrom

Country Status (27)

Country Link
US (1) US10493074B2 (enExample)
EP (1) EP3285772B1 (enExample)
JP (1) JP6721606B2 (enExample)
KR (1) KR102627370B1 (enExample)
CN (1) CN107530344B (enExample)
AR (1) AR105552A1 (enExample)
AU (1) AU2016251236B2 (enExample)
BR (1) BR112017020591B8 (enExample)
CA (1) CA2981631C (enExample)
CL (1) CL2017002669A1 (enExample)
CO (1) CO2017010573A2 (enExample)
CY (1) CY1122572T1 (enExample)
DK (1) DK3285772T3 (enExample)
EA (1) EA032432B1 (enExample)
ES (1) ES2763335T3 (enExample)
GB (1) GB201506786D0 (enExample)
HR (1) HRP20192273T1 (enExample)
HU (1) HUE047162T2 (enExample)
IL (1) IL254766B (enExample)
LT (1) LT3285772T (enExample)
MX (1) MX2017013148A (enExample)
MY (1) MY192972A (enExample)
PL (1) PL3285772T3 (enExample)
PT (1) PT3285772T (enExample)
SG (1) SG11201707789YA (enExample)
SI (1) SI3285772T1 (enExample)
WO (1) WO2016170014A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55546B1 (sr) * 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
PL2137186T3 (pl) * 2007-03-23 2016-09-30 Związki heterocykliczne i ich zastosowania
AP2012006294A0 (en) * 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AR082799A1 (es) 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
NZ714710A (en) * 2013-06-14 2016-11-25 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors

Also Published As

Publication number Publication date
US20180092921A1 (en) 2018-04-05
EP3285772A1 (en) 2018-02-28
JP2018513862A (ja) 2018-05-31
EP3285772B1 (en) 2019-10-02
MX2017013148A (es) 2018-02-21
BR112017020591B8 (pt) 2023-05-16
BR112017020591A2 (pt) 2018-07-03
BR112017020591B1 (pt) 2023-02-07
HUE047162T2 (hu) 2020-04-28
EA032432B1 (ru) 2019-05-31
CN107530344A (zh) 2018-01-02
HRP20192273T1 (hr) 2020-03-06
KR102627370B1 (ko) 2024-01-18
US10493074B2 (en) 2019-12-03
SG11201707789YA (en) 2017-11-29
EA201792318A1 (ru) 2018-05-31
LT3285772T (lt) 2020-01-10
ES2763335T3 (es) 2020-05-28
MY192972A (en) 2022-09-20
IL254766A0 (en) 2017-12-31
CL2017002669A1 (es) 2018-05-11
CA2981631C (en) 2023-02-21
PT3285772T (pt) 2020-01-14
GB201506786D0 (en) 2015-06-03
CY1122572T1 (el) 2021-01-27
AU2016251236A1 (en) 2017-11-09
IL254766B (en) 2020-05-31
CO2017010573A2 (es) 2018-03-09
AU2016251236B2 (en) 2018-06-14
SI3285772T1 (sl) 2020-02-28
AR105552A1 (es) 2017-10-18
PL3285772T3 (pl) 2020-05-18
CN107530344B (zh) 2020-03-17
KR20170140245A (ko) 2017-12-20
WO2016170014A1 (en) 2016-10-27
JP6721606B2 (ja) 2020-07-15
CA2981631A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
IL258402A (en) Electroporation for obesity or diabetes treatment
DK3609535T3 (da) Hbv-vaccine
EP3871633C0 (en) Elastic coated orthodontic appliance
DK3556775T3 (da) Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
EP3529459A4 (en) GEOLOGICAL GUIDANCE CORRECTED BY TOTAL VERTICAL DEPTH (TVD)
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
EP3298461C0 (en) ANALOGUE WELL-BEING DEVICE
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
PL3978074T3 (pl) Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1
DK3512506T3 (da) Anvendelse af pridopidin til behandling af retts syndrom
FI20146084A7 (fi) Monitoimikaarilauta
DK3556383T3 (da) Plasminogen til anvendelse ved behandling af diabetes
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3445157T3 (da) Udtrækkelig plantebakkeenhed
DK3666258T3 (da) Fremgangsmåde til behandling af prader-willis syndrom
HUE047756T2 (hu) Eljárás metil-merkaptán elõállítására
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner